CA2182568A1 - Novel carbamate derivative and medicinal composition containing the same - Google Patents

Novel carbamate derivative and medicinal composition containing the same

Info

Publication number
CA2182568A1
CA2182568A1 CA002182568A CA2182568A CA2182568A1 CA 2182568 A1 CA2182568 A1 CA 2182568A1 CA 002182568 A CA002182568 A CA 002182568A CA 2182568 A CA2182568 A CA 2182568A CA 2182568 A1 CA2182568 A1 CA 2182568A1
Authority
CA
Canada
Prior art keywords
group
compound
ring
carbamate
biphenylyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002182568A
Other languages
English (en)
French (fr)
Inventor
Makoto Takeuchi
Ryo Naito
Koichiro Morihira
Masahiko Hayakawa
Ken Ikeda
Yasuo Isomura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2182568A1 publication Critical patent/CA2182568A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D451/00Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CA002182568A 1994-02-10 1995-02-08 Novel carbamate derivative and medicinal composition containing the same Abandoned CA2182568A1 (en)

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
JPHEI-6-16829 1994-02-10
JP1682994 1994-02-10
JPHEI-6-35064 1994-03-04
JP3506494 1994-03-04
JP10257994 1994-05-17
JPHEI-6-102579 1994-05-17
JP22133594 1994-09-16
JPHEI-6-221335 1994-09-16
JP26741294 1994-10-31
JPHEI-6-267412 1994-10-31

Publications (1)

Publication Number Publication Date
CA2182568A1 true CA2182568A1 (en) 1995-08-17

Family

ID=27519861

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002182568A Abandoned CA2182568A1 (en) 1994-02-10 1995-02-08 Novel carbamate derivative and medicinal composition containing the same

Country Status (7)

Country Link
EP (1) EP0747355A4 (en:Method)
KR (1) KR970701174A (en:Method)
AU (1) AU685225B2 (en:Method)
CA (1) CA2182568A1 (en:Method)
HU (1) HUT76289A (en:Method)
TW (1) TW322478B (en:Method)
WO (1) WO1995021820A1 (en:Method)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat
US12060349B2 (en) 2012-09-11 2024-08-13 Genzyme Corporation Glucosylceramide synthase inhibitors
US12083115B2 (en) 2020-02-03 2024-09-10 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69739869D1 (de) * 1996-03-20 2010-06-17 Univ Wake Forest Health Sciences Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
WO1998054167A1 (en) * 1997-05-28 1998-12-03 Mitsubishi-Tokyo Pharmaceuticals, Inc. Indole compounds
DE69922494T2 (de) * 1998-02-04 2005-05-25 Banyu Pharmaceutical Co., Ltd. Zyklische n-acylamin-derivate
US6693202B1 (en) 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
US7214687B2 (en) 1999-07-14 2007-05-08 Almirall Ag Quinuclidine derivatives and medicinal compositions containing the same
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
ES2215688T3 (es) 1999-07-23 2004-10-16 Banyu Pharmaceutical Co., Ltd. Nuevos derivados amida.
MXPA02005596A (es) 1999-12-07 2004-09-10 Theravance Inc Derivados de carbamato con actividad antagonista para el rerceptor muscarinico.
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
AU2001255734A1 (en) 2000-04-27 2001-11-07 Wake Forest University Sigma-2 receptors as biomarkers of tumor cell proliferation
SI1300407T2 (sl) * 2000-06-27 2011-09-30 S A L V A T Lab Sa Karbamati, izvedeni iz arilalkilaminov
JP4445704B2 (ja) * 2000-12-22 2010-04-07 アルミラル・ソシエダッド・アノニマ キヌクリジンカルバメート誘導体およびm3アンダゴニストとしてのそれらの使用
PL363807A1 (en) 2000-12-28 2004-11-29 Almirall Prodesfarma Ag Novel quinuclidine derivatives and medicinal compositions containing the same
WO2003037317A1 (en) * 2001-10-26 2003-05-08 Dey, L.P. Albuterol inhalation solution, system, kit and method for relieving symptoms of pediatric asthma
EA006505B1 (ru) * 2001-12-20 2005-12-29 Лабораториос С.А.Л.В.А.Т.,С.А. Производные карбамата 1-алкил-1-азониабицикло[2.2.2]октана и их применение в качестве антагонистов мускаринового рецептора
KR101010905B1 (ko) 2002-01-18 2011-01-25 아스텔라스세이야쿠 가부시키가이샤 2-아실아미노티아졸 유도체 또는 그 염
ES2203327B1 (es) * 2002-06-21 2005-06-16 Almirall Prodesfarma, S.A. Nuevos carbamatos de quinuclidina y composiciones farmaceuticas que los contienen.
ES2204295B1 (es) 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
DE10255040A1 (de) * 2002-11-26 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Carbaminsäureester mit anticholinerger Wirksamkeit
US7041674B2 (en) * 2002-11-26 2006-05-09 Boehringer Ingelhiem Pharma Gmbh & Co. Kg Carbamic acid esters with anticholinergic activity
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN100569760C (zh) 2003-11-21 2009-12-16 施万制药 具有β2肾上腺素能受体激动剂和毒蕈碱性受体拮抗剂活性的化合物
TW200534855A (en) * 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
EP1723112A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528415A (ja) 2004-03-11 2007-10-11 セラヴァンス, インコーポレーテッド ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
EP1723108A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723110A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723113A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2006023460A2 (en) 2004-08-16 2006-03-02 Theravance, Inc. COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY
JP2008510014A (ja) 2004-08-16 2008-04-03 セラヴァンス, インコーポレーテッド β2アドレナリン作用性レセプターアゴニスト活性およびムスカリン性レセプターアンタゴニスト活性を有する化合物
US7479562B2 (en) 2005-03-10 2009-01-20 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099032A1 (en) 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
EP1866284A1 (en) 2005-03-10 2007-12-19 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1893577A1 (en) 2005-06-13 2008-03-05 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2007007282A2 (en) * 2005-07-11 2007-01-18 Ranbaxy Laboratories Limited Azabicyclo derivatives as muscarinic receptor antagonists
GB0602778D0 (en) 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
US7973055B2 (en) 2006-03-09 2011-07-05 Theravance, Inc. Crystalline forms of a biphenyl compound
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
TW200811104A (en) 2006-04-25 2008-03-01 Theravance Inc Crystalline forms of a dimethylphenyl compound
ES2298049B1 (es) 2006-07-21 2009-10-20 Laboratorios Almirall S.A. Procedimiento para fabricar bromuro de 3(r)-(2-hidroxi-2,2-ditien-2-ilacetoxi)-1-(3-fenoxipropil)-1-azoniabiciclo (2.2.2) octano.
WO2008041184A2 (en) * 2006-10-03 2008-04-10 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
EP2119716A4 (en) * 2007-02-09 2011-06-01 Astellas Pharma Inc AZA BRIDGE CYCLE COMPOUND
CN103145711A (zh) * 2007-03-23 2013-06-12 雅培制药有限公司 氮杂金刚烷酯和氨基甲酸酯衍生物及其使用方法
EP2100598A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2100599A1 (en) 2008-03-13 2009-09-16 Laboratorios Almirall, S.A. Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
EP2206712A1 (en) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. "Alkaloid aminoester derivatives and medicinal composition thereof"
EP2453894B1 (en) 2009-07-15 2015-11-04 Theravance Biopharma R&D IP, LLC Crystalline freebase form of a biphenyl compound
WO2012042539A2 (en) 2010-09-28 2012-04-05 Panacea Biotec Ltd Novel bicyclic compounds
RU2585767C2 (ru) * 2010-11-26 2016-06-10 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Производные глицина и их применение в качестве антагонистов мускариновых рецепторов
MX365245B (es) * 2011-03-18 2019-05-28 Genzyme Corp Inhibidores de glucosilceramida sintasa.
EP2510928A1 (en) 2011-04-15 2012-10-17 Almirall, S.A. Aclidinium for use in improving the quality of sleep in respiratory patients
SG11201506415XA (en) * 2013-03-15 2015-09-29 Genzyme Corp Method of preparing glucosylceramide synthase inhibitors
KR101538846B1 (ko) * 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
WO2017114377A1 (zh) * 2015-12-29 2017-07-06 四川海思科制药有限公司 一种苯基杂环衍生物及其在医药上的用途
SG11201901431PA (en) 2016-08-26 2019-03-28 Dong A St Co Ltd Novel salt of (r)-(1-methylpyrrolidine-3-yl)methyl(3'-chloro-4'-fluoro-[1,1'-biphenyl]-2-yl)carbamate and a crystal form thereof
KR102239776B1 (ko) * 2016-08-26 2021-04-13 동아에스티 주식회사 (r)-(1-메틸피롤리딘-3-일)메틸(3'-클로로-4'-플루오로-[1,1'-비페닐]-2-일)카바메이트의 신규염 및 이의 결정형
WO2019096226A1 (en) 2017-11-16 2019-05-23 Chengdu Easton Biopharmaceuticals Co., Ltd. Pasylated vegfr/pdgfr fusion proteins and their use in therapy
US20200308168A1 (en) * 2017-12-04 2020-10-01 Friedrich-Alexander-Universität Erlangen-Nürnberg Fluorophenyl substituted muscarinic receptor ligands with selectivity for m3 over m2
CN115850157A (zh) * 2022-11-30 2023-03-28 济南大学 一种1-苄基哌啶-4-基[1,1'-联苯]-2-基氨基甲酸酯的制备方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0972773A1 (en) * 1992-03-31 2000-01-19 Glaxo Group Limited 2-Oxadiazolyl- or 2-thiadiazolyl-phenylcarbamate and -phenylurea derivatives, their preparation and their use as intermediates

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12060349B2 (en) 2012-09-11 2024-08-13 Genzyme Corporation Glucosylceramide synthase inhibitors
US12083115B2 (en) 2020-02-03 2024-09-10 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Also Published As

Publication number Publication date
HUT76289A (en) 1997-07-28
AU1590995A (en) 1995-08-29
EP0747355A4 (en) 1997-04-09
HU9602188D0 (en) 1996-10-28
EP0747355A1 (en) 1996-12-11
TW322478B (en:Method) 1997-12-11
KR970701174A (ko) 1997-03-17
AU685225B2 (en) 1998-01-15
WO1995021820A1 (en) 1995-08-17

Similar Documents

Publication Publication Date Title
CA2182568A1 (en) Novel carbamate derivative and medicinal composition containing the same
KR100386487B1 (ko) 신규한퀴누클리딘유도체및이의약제학적조성물
DE69331103T2 (de) Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
EP0675886B1 (en) Aminomethylene substituted non-aromatic heterocycles and use as substance p antagonists
CA2218913C (en) Substituted oximes, hydrazones and olefins as neurokinin antagonists
DE69717845T2 (de) Substituierte oximderivate anwendbar als neurokinin-antagonisten
EP1499596B1 (en) Muscarinic antagonists
DE69024663T2 (de) Muscarin-rezeptor-antagonisten
EP1955697B1 (en) 2-aminobenzamide derivatives as vanilloid receptor 1 (vr1) inhibitors useful for the treatment of pain or bladder function disorder
US7781430B2 (en) Benzoxazole carboxamides for treating CINV and IBS-D
PL192397B1 (pl) Pochodna 1-(1,2-dipodstawionej piperydynylo)-4-piperydyny, jej zastosowanie, sposób wytwarzania i kompozycja farmaceutyczna
EP1699783B1 (en) Opioid receptor antagonists
JPH01106882A (ja) 5−ht受容体拮抗剤として有用な新規ベンズイミダゾリン−2−オキソ−1−カルボン酸誘導体
MX2007001540A (es) Compuestos amido y sus usos como farmaceuticos.
PT763031E (pt) Derivados da piperazina como antagonistas 5ht1a
US6710042B2 (en) Human NK3 receptor-selective antagonist compounds, method for obtaining them and pharmaceutical compositions containing them
CZ362599A3 (cs) Indazolamidové sloučeniny jako serotoninergní přípravky
JP2006522792A (ja) 4−フェニル−ピペリジン化合物およびそのオピオイド受容体のモジュレーターとしての使用
US7101892B2 (en) Sulfone derivatives as 5-HT7 receptor ligands
US5190953A (en) Heterocyclic carboxylic acid amides and esters of azabicyclic compounds as gastric prokinetic, antiemetic, anxiolytic and antiarrhythmic agents
US7576105B2 (en) Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives
NZ250580A (en) 3-(hetero)aryloxymorphinan derivatives and their use in the manufacture of medicaments
EP0690845B1 (en) Piperazine derivatives as 5-ht1a ligands
JPH08198751A (ja) カルバメート誘導体
JPH07258250A (ja) エステル誘導体

Legal Events

Date Code Title Description
FZDE Dead